National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

udenafil
A benzenesulfonamide derivative with vasodilatory activity. Udenafil selectively inhibits phosphodiesterase type 5 (PDE5), thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis; inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection. This agent does not significantly inhibit the PDE11 isozyme; PDE11 inhibition may be associated with significant myalgia. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:Zydena



Previous:tyroserleutide, tyrosinase peptide, tyrosine kinase inhibitor OSI-930, tyrosine kinase inhibitor XL228, Tysabri
Next:Ultandren, Ultane, Ultiva, ultralow-molecular-weight heparin AVE5026, Unasyn

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov